Products for Research Use Only
RegisterLogin

MPT0B392

CAT: 0804-HY-101287-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-101287-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line[1].
CAS Number
1346169-92-3
UNSPSC
12352005
Target
Apoptosis; Caspase; JNK; Microtubule/Tubulin
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mpt0b392.html
Purity
99.63
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=C2C(N=C(S(=O)(C3=CC(OC)=C(OC)C(OC)=C3)=O)C=C2)=CC=C1OC
Molecular Formula
C19H20N2O6S
Molecular Weight
404.44
References & Citations
[1]Chao MW, et al. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. Oncotarget. 2017 Apr,8 (17) :27772-27785.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase; JNK

Related Products

CatalogName
HY-145426-01MPT0B390
HY-122151MPT0B002

Alternative Products

CatalogName
T13779-01MPT0B392
A20378-50MPT0B392 50mg
A20378-25MPT0B392 25mg
A20378-10MPT0B392 10mg
A20378-5MPT0B392 5mg
A20378-100MPT0B392 100mg
A20378-1MPT0B392 1mg

Popular Products